Physician profile
Michaela D Mccargar
NPI 1023764487
$4,575.29
in general payments reported to CMS, 2019-2025
19 companies · $593 in 2025
The $593 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $577 · 2023: $1,624 · 2024: $1,782 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,863 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,863.47 |
| Education | $135.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $815.89 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $442.55 | 2022-2025 | Dupixent, Libtayo |
| Pfizer INC. | $402.49 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $362.91 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $359.90 | 2023-2025 | Sotyktu |
| Genzyme Corporation | $357.52 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $337.20 | 2022-2024 | Ilumya |
| Lilly USA, LLC | $295.66 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $258.04 | 2022-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $187.28 | 2022-2024 | Vtama |
| Janssen Biotech, INC. | $184.88 | 2023-2024 | Tremfya |
| Incyte Corporation | $159.23 | 2022-2025 | Opzelura |
| Ucb, INC. | $142.49 | 2022-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $79.00 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.88 | 2023 | Cyltezo, Spevigo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $42.23 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Leo Pharma INC. | $41.20 | 2024-2025 | Adbry, Anzupgo |
| Glaxosmithkline, LLC. | $26.62 | 2024 | Nucala |
| Ars Pharmaceuticals Operations, INC. | $21.32 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michaela Mccargar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.